Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Molindone · Moban, SPN-810

Small molecule · developed by Chartwell Rx

Approved FDA, Jan 1974
1 Registered trials

What is Molindone?

Molindone (SPN-810) is a drug studied in attention deficit hyperactivity disorder (ADHD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Moban, SPN-810
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Chartwell Rx
In trials of
SUPN
FDA status
Approved as Moban (January 18, 1974), NDA017111
UNII
RT3Y3QMF8N

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02691182 Phase 3 Attention Deficit Hyperactivity Disorder (ADHD) Terminated SUPN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Attention Deficit Hyperactivity Disorder (ADHD)

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.